Evidence map›Paper›PMID 39917007›Full record

ArticleCytoJournal2024

Investigating the role of exosomal microRNA-5703 in modulating tumor-associated endothelial cells in lung cancer.

Bing Wen, Rancen Tao, Yuyu Liu, Zhenfa Zhang

Abstract read
In one paragraph

Article in CytoJournal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bing WenDepartment of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Rancen TaoDepartment of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yuyu LiuOutpatient department, The Second People's Hospital of Yibin, Yibin, Sichuan, China.
Zhenfa ZhangDepartment of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Lung cancer, as a prevalent malignancy, continues to be a considerable clinical challenge. This study aimed to elucidate the role of microRNA-5703 (miR-5703) in lung cancer progression and to assess the effect of exosomal miR-5703 on tumor-associated endothelial cells (TAECs). Material and Methods: We analyzed Gene Expression Omnibus datasets and performed quantitative real-time polymerase chain reaction to determine miR-5703 expression levels in lung cancer tissues. Exosomes derived from lung cancer cells were identified, and the effects of miR-5703 inhibitors or mimics on malignant biological behavior were evaluated in the lung cancer cells. Moreover, to understand these effects on TAECs, we assessed angiogenesis, endothelial-mesenchymal transition (EndMT), and barrier function after treatment with miR- 5703 inhibitors or the exosome-assimilated inhibitor cytochalasin D. Tumor-bearing mouse models were used in validating the tumor-promoting effects of exosomes derived from lung cancer cells, and the markers of angiogenesis, EndMT, and barrier function were examined. Results: Our results showed that miR-5703 was up-regulated in the lung cancer cells and patient-derived exosomes. miR-5703 facilitated cell growth, migration, invasion, in LC cells, and impaired the barrier function, which promoted angiogenesis and EndMT of TAECs by carrying in exosomes through targeting inhibitor of growth family member 4 (ING4) was identified as target of miR-5703 ( Conclusion: miR-5703 operates as an oncogenic factor in lung cancer. After being taken up by TAECs, exosomal miR-5703 promotes angiogenesis, EndMT, and barrier damage by targeting ING4. Hence, miR-5703 is a potential target in the lung cancer microenvironment.

Indexed as

exosomelung cancerMicroRNAtumor-associated endothelial cell

Identifiers

PMID39917007
PMCPMC11801689

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.